TAK 070
Alternative Names: TAK-070Latest Information Update: 04 Nov 2017
At a glance
- Originator Takeda
- Developer University of Tokyo
- Class Antidementias
- Mechanism of Action BACE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Alzheimer's-disease(In the elderly, In volunteers) in Japan (PO)
- 11 Mar 2013 Phase-I clinical trials in Alzheimer's disease (in the elderly, in volunteers) in Japan (PO)
- 08 Jun 2012 TAK 070 licensed to the University of Tokyo